None listed
Conditions
Brief summary
This pilot study will test whether transcutaneous spinal cord stimulation (tSCS) using the open-source OpenXstim device is safe and practical for children and adults with long-term neurological conditions, including spinal cord injury, cerebral palsy, stroke, Parkinson’s disease, or multiple sclerosis (MS). Participants will attend about 48 supervised sessions over up to six months. The study hypothesis is that tSCS can be delivered safely and that most participants will be able to complete the planned treatment program. Primary outcomes include any device-related side effects and measures of feasibility, such as recruitment, adherence, and retention. Secondary outcomes will assess changes in movement, muscle stiffness, walking ability, pain, and quality of life at the end of treatment and at 1-, 3-, and 6-month follow-ups.
Interventions
Device/Procedure Transcutaneous spinal cord stimulation (tSCS) will be delivered using the OpenXstim, an open-source, programmable constant-current stimulator. Protocol Details Electrode placement: Two cathode electrodes will be positioned midline over the T11–L1 and L1–L2 vertebral levels. Two large anode electrodes will be placed over the left and right iliac crests. Waveform and stimulation parameters: Monophasic or biphasic constant-current pulses (carrier frequency 5–10 kHz; stimulation frequency 5–40 Hz) will be selected empirically by a licensed physiotherapist or clinician with prior neuromodulation experience. Parameters, including waveform type and stimulation intensity, will be adjusted at each session according to the participant’s real-time response to achieve comfortable stimulation below the motor threshold, typically 10–60 mA and within device safety limits. Session schedule: Sessions will last 30–45 minutes, administered 2–3 times per week for 4–6 consecutive months (approximately 48 sessions). The frequency and timing of sessions are based on participant and clinician availability while maintaining a consistent dose (approximately every other day to every three days). Administration and setting: All sessions will be delivered in a clinical setting (e.g., physiotherapy clinic) that adheres to standard hygiene and safety protocols. A licensed physiotherapist or clinician experienced in neuromodulation will conduct all interventions. Ramp-up and ramp-down: Stimulation current will be gradually increased over approximately 10 seconds to the target level at the start of each session and decreased over a similar period at the end, following established protocols in the literature and prior studies. Safety and monitoring: Participant comfort and skin integrity will be checked continuously during stimulation. Blood pressure, blood oxygenation, and other routine safety measures will be recorded. Adherence and fidelity: Attendance and stimulation parameters will be documented in a confidential logbook for each session to monitor adherence and allow analysis of session completion and protocol fidelity.
Sponsors
Study design
Eligibility
Inclusion criteria
• Children or adults aged 2 to 65 years • Diagnosis of spinal cord injury, cerebral palsy, stroke, or Parkinson’s disease, at least 12 months post-onset or medically stable • Ability to provide informed consent or assent; for minors, written consent provided by a parent or guardian
Exclusion criteria
• Implanted electronic devices (e.g., pacemaker, deep brain stimulator) • Uncontrolled epilepsy • Active skin lesions at electrode placement sites • Significant cardiac arrhythmia or unstable cardiovascular disease • Pregnancy